
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Description
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crack and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an immune system response that causes the inflamed skin and other symptoms.
Atopic dermatitis (eczema) symptoms include dry, cracked skin, itchiness, rash, bumps, on brown or black skin, oozing and crusting, thickened skin, darkening of the skin around the eyes, raw, sensitive skin from scratching.
Healthcare provider will diagnose eczema examining the skin. However, the following tests may be performed for confirmation, an allergy skin test, blood tests and a skin biopsy to distinguish one type of dermatitis from another.
Treatment of atopic dermatitis starts with moisturizing and self-care habits. These are sometimes combined with other treatments like medications and therapies. Medications including products applied to the skin, anti-infective drugs and anti-inflammatories. Therapies like wet dressings, light therapy and counselling may also help based on the severity.
There are many clinical trials ongoing in atopic dermatitis drug development. Some of the most promising trials are studying new treatments for atopic dermatitis, such as biologic drugs. Biologic drugs are made from living cells and are designed to target specific parts of the immune system. They have the potential to be more effective and have fewer side effects than traditional drugs. Other clinical trials are studying new ways to deliver existing treatments, such as through patches or creams.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Atopic Dermatitis treatment such as ARQ-151, Delgocitinib, FURESTEM-AD, and others. Key players involved in the development of therapies to treat atopic dermatitis are AbbVie, Akesobio Australia Pty Ltd, AstraZeneca, Amgen, AOBiome LLC and others. One drug is under late stage pre-registration, Nine drugs are under Phase III clinical trials and 60+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
In June 2022, The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. A regulatory filing for this age group is under review by the European Medicines Agency and the company is planning for submissions to regulatory authorities in additional countries and the preparations are underway.
Report Highlights
Global Insight Service's, Atopic Dermatitis - Drug Pipeline Landscape, 2023 report provides an overview of the Atopic Dermatitis pipeline drugs. This report covers detailed insights on Atopic Dermatitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Atopic Dermatitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crack and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an immune system response that causes the inflamed skin and other symptoms.
Atopic dermatitis (eczema) symptoms include dry, cracked skin, itchiness, rash, bumps, on brown or black skin, oozing and crusting, thickened skin, darkening of the skin around the eyes, raw, sensitive skin from scratching.
Healthcare provider will diagnose eczema examining the skin. However, the following tests may be performed for confirmation, an allergy skin test, blood tests and a skin biopsy to distinguish one type of dermatitis from another.
Treatment of atopic dermatitis starts with moisturizing and self-care habits. These are sometimes combined with other treatments like medications and therapies. Medications including products applied to the skin, anti-infective drugs and anti-inflammatories. Therapies like wet dressings, light therapy and counselling may also help based on the severity.
There are many clinical trials ongoing in atopic dermatitis drug development. Some of the most promising trials are studying new treatments for atopic dermatitis, such as biologic drugs. Biologic drugs are made from living cells and are designed to target specific parts of the immune system. They have the potential to be more effective and have fewer side effects than traditional drugs. Other clinical trials are studying new ways to deliver existing treatments, such as through patches or creams.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Atopic Dermatitis treatment such as ARQ-151, Delgocitinib, FURESTEM-AD, and others. Key players involved in the development of therapies to treat atopic dermatitis are AbbVie, Akesobio Australia Pty Ltd, AstraZeneca, Amgen, AOBiome LLC and others. One drug is under late stage pre-registration, Nine drugs are under Phase III clinical trials and 60+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
In June 2022, The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. A regulatory filing for this age group is under review by the European Medicines Agency and the company is planning for submissions to regulatory authorities in additional countries and the preparations are underway.
Report Highlights
Global Insight Service's, Atopic Dermatitis - Drug Pipeline Landscape, 2023 report provides an overview of the Atopic Dermatitis pipeline drugs. This report covers detailed insights on Atopic Dermatitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Atopic Dermatitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
388 Pages
- 1. Introduction
- 1.1 Atopic Dermatitis - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Atopic Dermatitis
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Atopic Dermatitis - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Late Stage Drugs-Pre-Registration
- 5.1.1 Dupilumab
- 5.2 Clinical Stage Drugs-Phase III
- 5.2.1 ARQ-151
- 5.2.2 delgocitinib
- 5.2.3 FURESTEM-AD
- 5.2.4 KHK4083/AMG 451
- 5.2.5 Lebrikizumab
- 5.2.6 Ruxolitinib
- 5.2.7 SHR0302
- 5.2.8 Tapinarof
- 5.2.9 Tradipitant
- 5.3 Clinical Stage Drugs-Phase II
- 5.3.1 611
- 5.3.2 ADSTEM
- 5.3.3 AK002
- 5.3.4 AK120
- 5.3.5 Amlitelimab
- 5.3.6 AMTX-100
- 5.3.7 Antroquinonol
- 5.3.8 Apremilast
- 5.3.9 ARQ-252
- 5.3.10 ASN002
- 5.3.11 ATI-1777
- 5.3.12 ATx201
- 5.3.13 B244
- 5.3.14 BEN2293
- 5.3.15 Benralizumab
- 5.3.16 BMS-986166
- 5.3.17 BMX-010
- 5.3.18 Branebrutinib
- 5.3.19 BTX 1204
- 5.3.20 CBP-201
- 5.3.21 CBP-201
- 5.3.22 CC-93538
- 5.3.23 CM310
- 5.3.24 CM326
- 5.3.25 CMK389
- 5.3.26 DBI-001
- 5.3.27 DBI-002
- 5.3.28 Difelikefalin
- 5.3.29 EBI-01
- 5.3.30 EDP1815
- 5.3.31 Etrasimod
- 5.3.32 FB-401
- 5.3.33 FB825
- 5.3.34 FMX114
- 5.3.35 GBR 830
- 5.3.36 GM-XANTHO
- 5.3.37 HPP737
- 5.3.38 HY209
- 5.3.39 ICP-332
- 5.3.40 IL-13Ra1 subunit
- 5.3.41 Jacketinib
- 5.3.42 KY1005
- 5.3.43 LNK01004
- 5.3.44 LP0145
- 5.3.45 LP0190
- 5.3.46 LP0201
- 5.3.47 LR19019
- 5.3.48 MSB-0221
- 5.3.49 Orismilast
- 5.3.50 PF-07038124
- 5.3.51 PH-10
- 5.3.52 Q301
- 5.3.53 Rilzabrutinib
- 5.3.54 Risankizumab
- 5.3.55 RPT193
- 5.3.56 SB011
- 5.3.57 SCD-044
- 5.3.58 SCM-AGH
- 5.3.59 STMC-103H
- 5.3.60 TER-101
- 5.3.61 Thykamine
- 5.3.62 Tozorakimab
- 5.3.63 UCB1381
- 5.3.64 UCB9741
- 5.3.65 ZEP-3Na
- 5.4 Clinical Stage Drugs-Phase I
- 5.4.1 9MW1911
- 5.4.2 AR100DP1
- 5.4.3 ASN008
- 5.4.4 Atopic Dermatitis Program
- 5.4.5 BBI-02
- 5.4.6 BioLexa
- 5.4.7 BSI-045B
- 5.4.8 CUG-252
- 5.4.9 EDP1867
- 5.4.10 EVO101
- 5.4.11 F0042
- 5.4.12 GR1802
- 5.4.13 GSK1070806
- 5.4.14 IMG-007
- 5.4.15 KBL693
- 5.4.16 KT-474/SAR444656
- 5.4.17 LY3471851
- 5.4.18 LY3844583
- 5.4.19 MK-6194
- 5.4.20 PBI-100
- 5.4.21 PF-06817024
- 5.4.22 PF-07242813
- 5.4.23 PF-07259955
- 5.4.24 PF-07275315
- 5.4.25 PF-07295324
- 5.4.26 QY201
- 5.4.27 RBN-3143
- 5.4.28 SAR443726
- 5.4.29 SB414
- 5.4.30 si-544
- 5.4.31 TQH2722
- 5.5 Early Stage Drugs-IND/CTA Filed
- 5.5.1 BRE-AD01
- 5.5.2 BSI-045A
- 5.5.3 LNK01004
- 5.5.4 OR101
- 5.5.5 PV-10
- 5.6 Early Stage Drugs-Preclinical
- 5.6.1 AD Project
- 5.6.2 AKP03
- 5.6.3 AKP07
- 5.6.4 ATB1606
- 5.6.5 Atopic dermatitis
- 5.6.6 Atopic Dermatitis Program
- 5.6.7 AV‑001
- 5.6.8 AVI-3307
- 5.6.9 AZT-01
- 5.6.10 BA2101
- 5.6.11 BBI-03
- 5.6.12 BIO-11006
- 5.6.13 Brilacidin
- 5.6.14 BV200
- 5.6.15 BX005-A
- 5.6.16 BZ371
- 5.6.17 CSA-144
- 5.6.18 CVXL-0255
- 5.6.19 Filaggrin-RMR
- 5.6.20 H4 antagonist
- 5.6.21 IL-4/13 kinoid
- 5.6.22 ING-012
- 5.6.23 IPG7236
- 5.6.24 KINE-201C
- 5.6.25 Mab for Atopic Dermatitis
- 5.6.26 MC2-11
- 5.6.27 MC2-22
- 5.6.28 MDH-011
- 5.6.29 MH004
- 5.6.30 NCP112
- 5.6.31 NM26- 2198
- 5.6.32 OM-85
- 5.6.33 PAR Pepducin
- 5.6.34 PDE4 inhibitors
- 5.6.35 PGUS-AD1
- 5.6.36 PJ2-01
- 5.6.37 PM-43I
- 5.6.38 QX005N
- 5.6.39 SHR-1819
- 5.6.40 SNG100
- 5.6.41 SVT-3A4610
- 5.6.42 SVT-3A4710
- 5.6.43 TI-520
- 5.6.44 Tofacitinib Citrate
- 5.6.45 Topical AD drug
- 5.6.46 TRPA1 antagonists
- 5.6.47 VM-AD
- 5.6.48 XZ.700
- 5.6.49 YR-001
- 5.7 Early Stage Drugs-Discovery
- 5.7.1 AD Project
- 5.7.2 Atopic Dermatitis Drug
- 5.7.3 Atopic Dermatitis Therapy
- 5.7.4 Drug for AD
- 5.7.5 Eczema Drug
- 5.7.6 INV-25
- 5.7.7 OC701
- 5.7.8 OM001
- 5.7.9 PAR2 mAb
- 5.7.10 Product for Eczema
- 5.7.11 RCI-003
- 5.7.12 TB16-8
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 3SBio Inc
- 9.2 AbbVie
- 9.3 Aclaris Therapeutics, Inc.
- 9.4 Akaal Pharma Pty Ltd
- 9.5 Akesobio Australia Pty Ltd
- 9.6 Alakos, Inc.
- 9.7 Amgen
- 9.8 Amtixbio Co Ltd
- 9.9 Amytrx Therapeutics, Inc
- 9.10 AOBiome LLC
- 9.11 Arcutis Biotherapeutics, Inc.
- 9.12 Arena Pharmaceuticals
- 9.13 Arjil Pharmaceuticals LLC
- 9.14 Asana BioSciences
- 9.15 ASLAN Pharmaceuticals
- 9.16 AstraZeneca
- 9.17 Atrapos Therapeutics LLC
- 9.18 Avixgen Inc
- 9.19 Azitra Inc
- 9.20 BenevolentAI Bio
- 9.21 BioMarck Pharmaceuticals Ltd
- 9.22 BioMimetix JV, LLC
- 9.23 BiomX, Inc
- 9.24 Biosion, Inc
- 9.25 Bioversys AG
- 9.26 Biozeus Pharmaceutical SA
- 9.27 Boryung ViGenCell Inc
- 9.28 Botanix Pharmaceuticals
- 9.29 Brandenburg Antiinfektiva GmbH
- 9.30 Brexogen Inc
- 9.31 Brickell Biotech, Inc
- 9.32 Bristol-Myers Squibb
- 9.33 CAGE Bio Inc.
- 9.34 Cara Therapeutics, Inc.
- 9.35 Celgene
- 9.36 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- 9.37 Clayton Biotechnologies Inc
- 9.38 Clevexel Pharma SA
- 9.39 CSA Biotechnologies LLC
- 9.40 Cugene Inc
- 9.41 Curexsys GmbH
- 9.42 Dermavant Sciences, Inc.
- 9.43 Derm-Biome Pharmaceuticals Inc
- 9.44 DermBiont Inc
- 9.45 Devonian
- 9.46 DongKoo Bio & Pharma Co Ltd
- 9.47 EHL Bio Co., Ltd.
- 9.48 Eli Lilly and Company
- 9.49 Enitiate Biopharmaceuticals (Hangzhou) Co Ltd
- 9.50 Epigen Biosciences Inc
- 9.51 Evelo Biosciences, Inc.
- 9.52 Evommune Inc
- 9.53 Forte Biosciences, Inc.
- 9.54 Genrix (Shanghai) Biopharmaceutical Co Ltd
- 9.55 GlaxoSmithKline
- 9.56 Golden Biotechnology Corporation
- 9.57 Hefei Medical & Pharmaceutical Co Ltd
- 9.58 Hoth Therapeutics, Inc
- 9.59 Ichnos Sciences SA
- 9.60 Incyte Corporation
- 9.61 Ingenew Pharmaceuticals Inc
- 9.62 Inmagene Biopharmaceuticals Ltd
- 9.63 InnoCare Pharma Ltd
- 9.64 Innovation Pharmaceuticals Inc
- 9.65 Innovimmune Biotherapeutics Inc
- 9.66 Intrinsic Medicine Inc
- 9.67 JiangSu Qyuns Therapeutics Co Ltd
- 9.68 Jupiter Wellness Inc
- 9.69 Kang Stem Biotech Co., Ltd.
- 9.70 Keymed Biosciences Co.Ltd
- 9.71 Kine Sciences
- 9.72 KoBioLabs Inc
- 9.73 Krystal Biotech Inc
- 9.74 Kymab Limited
- 9.75 Kymera Therapeutics, Inc.
- 9.76 Landos Biopharma Inc
- 9.77 Larix Bioscience LLC
- 9.78 LEO Pharma
- 9.79 LG Chem Ltd
- 9.80 Lipidor AB
- 9.81 Lynk Pharmaceuticals
- 9.82 Mabwell (Shanghai) Bioscience Co., Ltd.
- 9.83 Matrisys Bioscience Inc
- 9.84 MC2 Therapeutics AS
- 9.85 MD Healthcare Inc
- 9.86 Merck Sharp & Dohme LLC
- 9.87 Micreos BV
- 9.88 Minghui Pharmaceutical Pty Ltd
- 9.89 Nanjing Immunophage Biotech Co., Ltd
- 9.90 Neovacs SA
- 9.91 Nepsone ehf
- 9.92 Novan, Inc.|Novella Clinical
- 9.93 Novartis Pharmaceuticals
- 9.94 Numab Therapeutics AG
- 9.95 Oasis Pharmaceuticals LLC
- 9.96 OM Pharma Ltd
- 9.97 Oncocross Co Ltd
- 9.98 Oneness Biotech Co., Ltd.
- 9.99 Ornovi Inc
- 9.100 Pfizer
- 9.101 PrimeGen Global Inc
- 9.102 Provectus Pharmaceuticals
- 9.103 Pyramid Biosciences Inc
- 9.104 Qurient Co., Ltd.
- 9.105 RAPT Therapeutics, Inc.
- 9.106 Regeneron Pharmaceuticals
- 9.107 Reistone Biopharma Company Limited
- 9.108 Ribon Therapeutics, Inc.
- 9.109 Rudacure Co Ltd
- 9.110 Sanofi
- 9.111 SCM Lifescience Co., LTD.
- 9.112 Seanergy Dermatology Ltd.
- 9.113 selectION Therapeutics GmbH
- 9.114 Servatus Ltd
- 9.115 Shandong Boan Biotechnology Co Ltd
- 9.116 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- 9.117 Shanghai Hengrui Pharmaceutical Co., Ltd.
- 9.118 Shaperon
- 9.119 Shulov Innovate for Science Ltd. 2012
- 9.120 Siolta Therapeutics, Inc.
- 9.121 Sosei Group Corp
- 9.122 StemRIM Inc
- 9.123 Sterna Biologicals GmbH & Co. KG
- 9.124 Sun Pharmaceutical Industries Limited
- 9.125 Suzhou Connect Biopharmaceuticals, Ltd.
- 9.126 Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- 9.127 TaiwanJ Pharmaceuticals Co Ltd
- 9.128 TeraImmune Inc
- 9.129 Teres Bio, Inc.
- 9.130 Therabest Co Ltd
- 9.131 Tirmed Pharma AB
- 9.132 Torrent Pharmaceuticals Ltd
- 9.133 TRPblue Inc
- 9.134 UCB Pharma
- 9.135 UNION therapeutics
- 9.136 Vanda Pharmaceuticals
- 9.137 Vasomune Inc
- 9.138 vTv Therapeutics Inc
- 9.139 Vyne Therapeutics Inc.
- 9.140 Xantho Biotechnology Co., LTD
- 9.141 YIRUI Pharmaceutical Technology Co Ltd
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.2 Number of Products under Development by Atopic Dermatitis
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - ARQ-151/Arcutis Biotherapeutics, Inc.
- Table 2.2 Clinical Trial Details - delgocitinib/LEO Pharma
- Table 2.3 Clinical Trial Details - FURESTEM-AD/Kang Stem Biotech Co., Ltd.
- Table 2.4 Clinical Trial Details - KHK4083/AMG 451/Amgen
- Table 2.5 Clinical Trial Details - Lebrikizumab/Eli Lilly and Company
- Table 2.6 Clinical Trial Details - Ruxolitinib/Incyte Corporation
- Table 2.7 Clinical Trial Details - SHR0302 /Reistone Biopharma Company Limited
- Table 2.8 Clinical Trial Details - Tapinarof/Dermavant Sciences, Inc.
- Table 2.9 Clinical Trial Details - Tradipitant/Vanda Pharmaceuticals
- Table 2.10 Clinical Trial Details - ADSTEM/EHL Bio Co., Ltd.
- Table 2.11 Clinical Trial Details - AK002/Allakos, Inc.
- Table 2.12 Clinical Trial Details - AK120/Akesobio Australia Pty Ltd
- Table 2.13 Clinical Trial Details - Amlitelimab/Sanofi
- Table 2.14 Clinical Trial Details - AMTX-100/Amytrx Therapeutics, Inc
- Table 2.15 Clinical Trial Details - Antroquinonol/Golden Biotechnology Corporation
- Table 2.16 Clinical Trial Details - Apremilast/Amgen
- Table 2.17 Clinical Trial Details - ARQ-252/Arcutis Biotherapeutics, Inc.
- Table 2.18 Clinical Trial Details - ASN002/Asana BioSciences
- Table 2.19 Clinical Trial Details - ATI-1777/Aclaris Therapeutics, Inc.
- Table 2.20 Clinical Trial Details - ATx201/UNION therapeutics
- Table 2.21 Clinical Trial Details - B244/AOBiome LLC
- Table 2.22 Clinical Trial Details - BEN2293 /BenevolentAI Bio
- Table 2.23 Clinical Trial Details - Benralizumab/AstraZeneca
- Table 2.24 Clinical Trial Details - BMS-986166/Bristol-Myers Squibb
- Table 2.25 Clinical Trial Details - BMX-010/BioMimetix JV, LLC
- Table 2.26 Clinical Trial Details - Branebrutinib/Bristol-Myers Squibb
- Table 2.27 Clinical Trial Details - BTX 1204/Botanix Pharmaceuticals
- Table 2.28 Clinical Trial Details - CBP-201/Suzhou Connect Biopharmaceuticals, Ltd.
- Table 2.29 Clinical Trial Details - CBP-201/Suzhou Connect Biopharmaceuticals, Ltd.
- Table 2.30 Clinical Trial Details - CC-93538/Celgene
- Table 2.31 Clinical Trial Details - CM310/Keymed Biosciences Co.Ltd
- Table 2.32 Clinical Trial Details - CM326/Keymed Biosciences Co.Ltd
- Table 2.33 Clinical Trial Details - CMK389/Novartis Pharmaceuticals
- Table 2.34 Clinical Trial Details - DBI-001/DermBiont, Inc
- Table 2.35 Clinical Trial Details - difelikefalin /Cara Therapeutics, Inc.
- Table 2.36 Clinical Trial Details - EDP1815/Evelo Biosciences, Inc.
- Table 2.37 Clinical Trial Details - Etrasimod/Arena Pharmaceuticals
- Table 2.38 Clinical Trial Details - FB-401/Forte Biosciences, Inc.
- Table 2.39 Clinical Trial Details - FB825/Oneness Biotech Co., Ltd.
- Table 2.40 Clinical Trial Details - FMX114/Vyne Therapeutics Inc.
- Table 2.41 Clinical Trial Details - GBR 830/Ichnos Sciences SA
- Table 2.42 Clinical Trial Details - GM-XANTHO/Xantho Biotechnology Co., LTD
- Table 2.43 Clinical Trial Details - HY209 /Shaperon
- Table 2.44 Clinical Trial Details - Jacketinib/Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Table 2.45 Clinical Trial Details - KY1005/Kymab Limited
- Table 2.46 Clinical Trial Details - LP0145/LEO Pharma
- Table 2.47 Clinical Trial Details - Orismilast /UNION therapeutics
- Table 2.48 Clinical Trial Details - PF-07038124/Pfizer
- Table 2.49 Clinical Trial Details - PH-10/Provectus Pharmaceuticals
- Table 2.50 Clinical Trial Details - Q301 /Qurient Co., Ltd.
- Table 2.51 Clinical Trial Details - Rilzabrutinib/Sanofi
- Table 2.52 Clinical Trial Details - Risankizumab/AbbVie
- Table 2.53 Clinical Trial Details - RPT193/RAPT Therapeutics, Inc.
- Table 2.54 Clinical Trial Details - SB011/Sterna Biologicals GmbH & Co. KG
- Table 2.55 Clinical Trial Details - SCD-044/Sun Pharmaceutical Industries Limited
- Table 2.56 Clinical Trial Details - SCM-AGH/SCM Lifescience Co., LTD.
- Table 2.57 Clinical Trial Details - STMC-103H/Siolta Therapeutics, Inc.
- Table 2.58 Clinical Trial Details - TER-101/Teres Bio, Inc.
- Table 2.59 Clinical Trial Details - Tozorakimab/AstraZeneca
- Table 2.60 Clinical Trial Details - UCB1381/UCB Pharma
- Table 2.61 Clinical Trial Details - UCB9741/UCB Pharma
- Table 2.62 Clinical Trial Details - ZEP-3Na/Shulov Innovate for Science Ltd. 2012
- Table 2.63 Clinical Trial Details - 9MW1911 /Mabwell (Shanghai) Bioscience Co., Ltd.
- Table 2.64 Clinical Trial Details - AR100DP1/Arjil Pharmaceuticals LLC
- Table 2.65 Clinical Trial Details - ASN008 /Asana BioSciences
- Table 2.66 Clinical Trial Details - BBI-02/Brickell Biotech, Inc
- Table 2.67 Clinical Trial Details - BioLexa /Hoth Therapeutics, Inc
- Table 2.68 Clinical Trial Details - BSI-045B/Biosion, Inc
- Table 2.69 Clinical Trial Details - EDP1867/Evelo Biosciences, Inc.
- Table 2.70 Clinical Trial Details - GR1802 /Genrix (Shanghai) Biopharmaceutical Co Ltd
- Table 2.71 Clinical Trial Details - GSK1070806/GlaxoSmithKline
- Table 2.72 Clinical Trial Details - KT-474/SAR444656/Kymera Therapeutics, Inc.
- Table 2.73 Clinical Trial Details - LY3471851/Eli Lilly and Company
- Table 2.74 Clinical Trial Details - LY3844583/Eli Lilly and Company
- Table 2.75 Clinical Trial Details - MK-6194/Merck Sharp & Dohme LLC
- Table 2.76 Clinical Trial Details - PBI-100/Pyramid Biosciences Inc
- Table 2.77 Clinical Trial Details - PF-06817024/Pfizer
- Table 2.78 Clinical Trial Details - PF-07242813/Pfizer
- Table 2.79 Clinical Trial Details - PF-07259955/Pfizer
- Table 2.80 Clinical Trial Details - PF-07275315/Pfizer
- Table 2.81 Clinical Trial Details - PF-07295324/Pfizer
- Table 2.82 Clinical Trial Details - RBN-3143/Ribon Therapeutics, Inc.
- Table 2.83 Clinical Trial Details - SB414 /Novan, Inc.|Novella Clinical
- Table 2.84 Clinical Trial Details - si-544/selectION Therapeutics GmbH
- Table 2.85 Clinical Trial Details - TQH2722 /Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Atopic Dermatitis, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Atopic Dermatitis, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Atopic Dermatitis, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Atopic Dermatitis, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Atopic Dermatitis, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.